Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial
Kanwal Raghav(The University of Texas MD Anderson Cancer Center), Takayuki Yoshino(University of Tsukuba), Hisato Kawakami(Tohoku University), Kojiro Kobayashi(Daiichi Sankyo (United States)), Makito Koga(Daiichi-Sankyo (Japan)), Atsuo Takashima(National Cancer Center Hospital East), Hung‐Chih Hsu(Tamkang University), Marc Peeters(University of Antwerp), Salvatore Siena(University of Milan), Yongjun Cha(Seoul National University), Sara Lonardi(Istituto Oncologico Veneto), Daniel Barrios(Daiichi Sankyo (United States)), Yoshito Komatsu(Hokkaido University Hospital), Jeanne Tie(The Royal Melbourne Hospital), Filippo Pietrantonio(Fondazione IRCCS Istituto Nazionale dei Tumori), Thierry André(Inserm), John Allard(Daiichi Sankyo (United States)), Kensei Yamaguchi(Japanese Foundation For Cancer Research), Takeshi Kato(Osaka National Hospital), Qi Yan(Shanxi Medical University), Marc Van den Eynde(Cliniques Universitaires Saint-Luc), Takahiro Kamio(Daiichi Sankyo (United States)), Cristina Grávalos Castro(Research Institute Hospital 12 de Octubre), Aislyn Boran(Daiichi Sankyo (United States)), Tae‐You Kim(Seoul National University Hospital), John H. Strickler(Duke Medical Center)
Cited by 124
Related Papers
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
|New England Journal of Medicine|2020|2.9k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Detection and localization of surgically resectable cancers with a multi-analyte blood test
|Science|2018|2.8k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k